Journal of Cardiothoracic Surgery

FEBRUARY 9, 2024

Adult patients surviving with congenital heart disease (ACHD) is growing. We examine the factors associated with heart transplant outcomes in this challenging population with complex anatomy requiring redo-sur.

Congenital Heart Disease 52

Congenital Heart Disease Heart Transplant Transplant Congenital 52

Wellnest

JANUARY 24, 2024

Introduction: Wellnest brings you , the latest medical news where an infant successfully received a partial heart transplant! In a remarkable leap forward for pediatric cardiac care, a groundbreaking partial heart transplant procedure has emerged as a beacon of hope for infants facing severe congenital heart conditions.

Heart Transplant 52

Heart Transplant Transplant Pediatrics Congenital 52

Frontiers in Cardiovascular Medicine

JANUARY 10, 2024

Introduction Heart transplantation (HT) is the only treatment option in children with heart failure secondary to cardiomyopathies and non-reparable congenital heart diseases.

Heart Transplant 59

Heart Transplant Transplant Arrhythmia Congenital Heart Disease 59

Heart 2023 Conference

JANUARY 17, 2024

This institute is dedicated to pioneering research, innovation, and the development of clinically effective techniques for addressing various heart conditions. Additionally, it offers comprehensive cardiac screening and preventive care.

Congenital Heart Disease 49

Congenital Heart Disease Coronary Artery Disease Heart Transplant Transplant 49

Circulation: Heart Failure

FEBRUARY 1, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:In 2018, an algorithm-based allocation system for heart transplantation (HT) was implemented in France. The cumulative incidence of waitlist mortality estimated with competing risk analysis and incidence of transplantation were compared between diagnosis groups.

Heart Failure 40

Heart Failure Congenital Heart Disease Congenital Cardiomyopathy 40

DAIC

MARCH 6, 2024

Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly. 5 Kutty, S.,

Pediatrics 105

Pediatrics Ultrasound Heart Transplant Echocardiogram 105

Journal of Cardiovascular Electrophysiology

NOVEMBER 17, 2023

After excluding patients with congenital or rheumatic heart disease, heart transplant recipients, or those without baseline echocardiogram, a total of 130 patients were included in the analysis. Echocardiographic data were analyzed at baseline before ablation, and at early follow-up within 1-year postablation.

Atrial Flutter 40

Atrial Flutter Ablation Heart Transplant Tricuspid 40